UNSPSC 51393605: Bucladesine sodium

This classification denotes a phosphodiesterase inhibitor with the molecular formula C18H23N5O8P.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DZN2C97A7, chemically known as sodium dibutyryl cyclic adenosine-3,5-monophosphate but more generally known as bucladesine sodium, which bears US NIH Compound Identifier 28177. European Medicines Agency schedules Bucladesine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00888MIG.

Most nations, for tariff and trade purposes, schedule bucladesine sodium under HS 29349990 and SITC 51579. As of Q4 2014, BUCLADESINE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CCCC(=O)NC1C2C(NCN1)N(CN2)[C@H]3[C@@H]([C@H]4[C@H](O3)COP(=O)(O4)[O-])OC(=O)CCC.[NA+].

UNSPSC 51393605 Bucladesine sodium is a Commodity code that encompasses pharmaceutical and chemical compounds used in state and local health and human services programs. Recent state and local procurement activity under this code reflects demand for medications and drug-management systems tied to public health initiatives, particularly opioid-response and pharmacy benefit programs. State agencies and county health departments are the primary issuing bodies soliciting under the code, focused on procuring finished pharmaceutical products and related medical supplies for community health operations rather than raw chemical inputs.

Activity appears concentrated in Florida and Texas, with the most recent opportunity being Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level interest in direct pharmaceutical procurement arrangements outside traditional pharmacy benefit manager and group purchasing organization channels. The Seminole County contract includes a two-year initial term with one-year renewal option and imposes standard compliance requirements including E-Verify, drug-free workplace certification, and insurance coverage; potential FEMA funding introduces additional federal environmental and compliance mandates.